Immunodeficiency Therapeutics Market
Immunodeficiency disorders or diseases render the ability of the immune system to fight against microbial infection, thus making a person immuno-compromised. Thus, people suffering from immunodeficiency diseases or disorders are more likely to fall sick. An immunodeficiency disorder may be either congenital or acquired. Congenital immunodeficiency disorder refers to the one which occurs by birth while acquired disorder refers to the one which occurs later in life. For instance, primary immunodeficiency disease is a congenital immunodeficiency disease which is a result of defect in genes that regulate the immune system. These genes are involved in functioning of immune organs such as spleen, lymph nodes, bone marrow, tonsils, and others. Some of the common primary immunodeficiency diseases include X-linked agammaglobulinemia (XLA), common variable, immunodeficiency (CVID), and severe combined immunodeficiency (SCID). Human immunodeficiency virus, spleen removal surgery, unsanitary conditions, and malnutrition are the most common causes of immunodeficiency disorders. Immunodeficiency diseases or disorders may exhibit signs such as yeast infection, cold, pink eye, diarrhea, pneumonia, and others. Recent advances in the field of immunology and genetics has created large number of opportunities for development and commercialization of newer, safer, and more efficient immunodeficiency therapeutics.
Market Dynamics
Market players are conducting clinical trials for developing safer and more efficient treatments for immunodeficiency diseases, which could contribute to the growth of the global immunodeficiency therapeutics market over the forecast period. For instance, in March 2017, Octapharma AG, a Switzerland based pharmaceutical company initiated phase III clinical trial study to investigate the efficiency, safety and tolerability of its product Octanorm (cutaquig) which is a ready to use liquid formulation of normal human IgG to be administered subcutaneously for treatment of primary immunodeficiency disease. The results for this clinical study were published by PubMed in April 2020, and show that Octanorm, manufactured by Octapharma AG is safe for indicated use.
Market players are focusing on launch of products, which is expected to strengthen their position in the global immunodeficiency therapeutics market. For instance, in June 2019, Octapharma AG launched its new product called cutaquig which is a 16.5% immune globulin solution to be used for treatment of primary humoral immunodeficiency.
Market players are involved in inorganic business strategies such a partnership to strengthen their position globally, this is expected to drive the growth of the global immunodeficiency therapeutics market. For instance, in January 2020, SAB Biotherapeutics Inc., a U.S. based biotechnology company entered into a collaborative partnership with CSL Behring, a U.S. based biopharmaceutical company to carry out research based on novel therapies which could be used for treatment of immune disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), primary immunodeficiency disease, and others.
Key features of the study
Market Segmentation
Market Segmentation
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
